NCT06060704

Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.

Name: Clinical Trial NCT06060704
Creator: The First Affiliated Hospital with Nanjing Medical University
Keywords: Metastatic Colorectal Cancer, Envafolimab, Phase 2, drug, clinical trial, China

A Prospective, Open, Single-center, Single-arm Study to Explore Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of mCRC Patients Who Were Refractory to Second-line and Above Standard Therapy.

The First Affiliated Hospital with Nanjing Medical University·Phase 2·ClinicalTrials.gov·drugRecruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Metastatic Colorectal Cancer
Drug/Device/Intervention: Envafolimab
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: The First Affiliated Hospital with Nanjing Medical University
Location: Nanjing, China

Timeline & enrollment

Phase: Phase 2
Start date: Nov 01, 2023
End date: Sep 01, 2025
Enrollment: 33 participants

Primary outcome

ORR（Objective response rate）

Summary

The goal of this single-arm study is to evaluate the efficacy and safety of Envafolimab combined with Trifluridine/Tipiracil and Bevacizumab in the treatment of metastatic colorectal cancer patients who are refractory or intolerant to standard therapy.

ICD-10 classifications

Malignant neoplasm of colonMalignant neoplasm: Colon, unspecifiedMalignant neoplasm: Descending colonMalignant neoplasm: Ascending colonMalignant neoplasm: Overlapping lesion of colon

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06060704
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06060704 through Pure Global AI's free database. This Phase 2 trial is sponsored by The First Affiliated Hospital with Nanjing Medical University and is currently Recruiting. The study focuses on Metastatic Colorectal Cancer. Target enrollment is 33 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.